Tuesday 9 September 2008

Medarex Announces Presentations At The 33rd Congress Of The European Society For Medical Oncology

�Medarex, Inc.
(Nasdaq: MEDX) announced that nine clinical abstracts for ipilimumab,
an investigational anti-CTLA-4 antibody, in melanoma ar scheduled to be
the subject of presentations at the thirty-third Congress of the European Society
for Medical Oncology (ESMO) being held September 12-16, 2008 in Stockholm.
Many of the following abstracts will include updated one-year selection data
from three Phase 2 studies (008, 022 and 007) in antecedently treated
patients with in advance metastatic melanoma:

Ipilimumab Presentations in Advanced Melanoma



-- "Efficacy and safety of patients with ripe melanoma treated with
ipilimumab with or without the addition of prophylactic budesonide"
(Abstract #783P) I. Ron - Poster presentation from 12:45 p.m. to 1:45 p.m.
local time on Saturday, September 13, 2008.



-- "Treatment guidelines for the management of immune-related adverse
events in patients treated with ipilimumab, an anti-CTLA4 therapy"
(Abstract #787P) K. Chin - Poster discussion from 12:45 p.m. to 1:45 p.m.
local time on Saturday, September 13, 2008.



-- "Ipilimumab-mediated patterns of response in patients with
pretreated, advanced melanoma" (Abstract #784P) K. Harmankaya - Poster
demonstration from 12:45 p.m. to 1:45 p.m. local fourth dimension on Saturday, September
13, 2008.



-- "Clinical activity of ipilimumab in patients with sophisticated melanoma
and brain metastases" (Abstract #786P) J. S. Weber - Poster display
from 12:45 p.m. to 1:45 p.m. local fourth dimension on Saturday, September 13, 2008.



-- "Ipilimumab 10 mg/kg initiation dosing promotes T-cell activating in
patients with advanced melanoma" (Abstract #785P) A. Hoos - Poster
display and treatment from 12:45 p.m. to 1:45 p.m. local time on
Saturday, September 13, 2008.


-- "Effect of dose on efficacy and safety in ipilimumab-treated
patients with advanced melanoma - results from a Phase 2, randomized,
dose-ranging study" (Abstract #769O) C. Lebbe - Oral presentation from 3:30
p.m. to 5:30 p.m. local time on Monday, September 15, 2008.



-- "Efficacy and base hit of treatment-naive and antecedently treated
patients with sophisticated melanoma receiving ipilimumab" (Abstract #778PD) R.
Ridolfi - Poster discussion from 12:30 p.m. to 1:30 p.m. local time on
Monday, September 15, 2008.



-- "Efficacy and safety of ipilimumab in patients with advanced
malignant melanoma who had progressed on one or more prior therapies: results from a
single-arm, multicenter study" (Abstract #776PD) M. Maio - Poster
discourse from 12:30 p.m. to 1:30 p.m. local time on Monday, September 15,
2008.



-- "Prolonged stable disease in ipilimumab-treated patients with
advanced melanoma world Health Organization have progressed on prior anticancer therapies"
(Abstract #768O) V. Chiarion Sileni - Oral presentation from 3:30 p.m. to
5:30 p.m. local time on Monday, September 15, 2008.



More information most the ESMO Congress whitethorn be institute at http://www.esmo.org.

About Medarex



Medarex is a biopharmaceutical company focused on the breakthrough,
development and potential commercialisation of fully human antibody-based
therapeutics to treat severe and debilitating diseases, including
cancer, kindling, autoimmune disorders and infective diseases. Medarex
applies its UltiMAb(R) technology and product development and clinical
manufacture experience to generate, support and potentially commercialize
a broad range of in full human antibody product candidates for itself and its
partners. More than 40 of these therapeutic production candidates derived from
Medarex technology are in human clinical testing or let had INDs submitted
for such trials, with seven of the most advanced product candidates
currently in Phase 3 clinical trials or the subject of regulatory
applications for merchandising authorization. Medarex is committed to construction
value by developing a diverse pipeline of antibody products to address the
world's unmet healthcare needs. For more information around Medarex, visit
its site at http://www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks
of Medarex, Inc. All rights ar reserved.


Medarex, Inc.
http://www.medarex.com



More info

Wednesday 20 August 2008

Study Indicates Higher Incidence Of Childbirth-Related PTSD Than Previously Thought

�Nearly unrivaled in 10 U.S. women who have given birth recently meet the formal criteria for post-traumatic stress disorder resulting from childbearing, according to a survey released this week by the nonprofit maternity care group Childbirth Connection, the Wall Street Journal reports. Some aesculapian experts say that PTSD, most commonly linked to people wHO have experienced violent events, can as well be triggered by a painful or complicated labor and delivery in which a woman believes she or her child power die. PTSD can congeal in immediately or months after a traumatic event. According to the Journal, the condition often occurs when somebody has experient an event that includes actual or threatened sober injury or death and evokes intense fear or a intuitive feeling of helplessness. Symptoms of the experimental condition can include anxiety, flashbacks and a "numbness to daily life sentence," the Journal reports.

For the survey, titled "New Mothers Speak Out," Childbirth Connection commissioned Harris Interactive to screen 900 U.S. mothers using an established PSTD screening instrument. Nine percent of the women surveyed screened positive for all the criteria of PTSD outlined in the Diagnostic and Statistical Manual of Mental Disorders, and 18% of participants showed some signs of the condition, according to the theme. Researchers renowned that most women enrolled in the survey wHO experienced PTSD and other depression symptoms did non seek professional help. According to the Journal, the rate of PTSD among mothers has not been studied extensively, but separate studies conducted outside the U.S. estimated that betwixt 1.5% and 5.9% of mothers experience the condition. PTSD is thought to be far less vernacular in mothers than postpartum depression, which affects roughly 15% of mothers, according to the National Institute of Mental Health.

Health precaution providers trust the increasing number of obstetric procedures used in labor and delivery could be playing a role in PTSD. Cheryl Beck -- a professor at the University of Connecticut School of Nursing, world Health Organization served as an consultant for the study -- said the mothers reportage signs of PTSD had a higher rate of medical intervention and were more likely to draw feeling helpless in a threatening environment. A history of sexual abuse or other injury also potty increase a woman's danger of experiencing PTSD related to vaginal birth, the Journal reports.

According to the Journal, the survey's results ar "likely to add fuel to a debate roughly how to better key out and process maternal mode disorders and whether widespread, systemic screening is warranted." New Jersey in 2006 passed a law requiring women to be screened for hazard of low after existence discharged following childbirth, as well as at the first postnatal doctor's visit. Other states, including Illinois and Texas, have passed laws to increase educational awareness of postpartum mental conditions.

Federal legislation (S 1375) that would fund research into postpartum mood disorders and the effects of covering for the conditions failed to make the Senate floor last�month as voice of a legislative packet (S 3297), but supporters believe the bill could be reconsidered in the fall. Opponents of the measure have said the bill could lead to increased "drugging of mothers." Shari Lusskin, director of reproductive psychological medicine at New York University Medical Center, said many aspects of PTSD ar not full understood, specially childbirth-related PTSD. She aforementioned, "We don't want to overmedicalize a normal section of human development. Just because you had a traumatic nascency, doesn't bastardly you'll get PTSD" (Zimmerman, Wall Street Journal, 8/5).


Reprinted with kind permission from hTTP://www.nationalpartnership.org. You can persuasion the entire Daily Women's Health Policy Report, lookup the archives, or sign up for email manner of speaking here. The Daily Women's Health Policy Report is published by the National Partnership for Women and families.

� 2007 National Partnership for Women & Families. All rights reserved.


More info

Sunday 10 August 2008

Pediatric HIV Treatment Increases Asthma Risk

� Medication often recommended to address HIV in children may increase their risk of developing asthma, according to new research published in July

Wednesday 2 July 2008

Lykke Li U.S. Live Dates Announced

Sweden's Lykke Li has mapped-out live dates in North America, with dates set to be held in August, October and November.


These ten performances coincide with the release of 'Youth Novels' - her debut album, that will finally see the light of day in the U.S. on August 19th, via her own label LL Recordings.


Lykke Li released the LP in the UK last month and you can read our review here, and watch a video for lead single 'I'm Good, I'm Gone' here.


August Dates:


Los Angeles, CA Hotel Caf� (25)

New York, NY Le Poisson Rouge (28)


October Dates:


Washington, DC Black Cat (19)

Boston, MA Paradise (23)

Toronto, ON Mod Club (24)

Chicago, IL Empty Bottle (25)

Vancouver, BC Richards on Richards (28)

Seattle, WA Neumo's (29)

Portland, OR Doug Fir (30)


November Dates:


San Francisco, CA Independent (1)




See Also

Sunday 22 June 2008

Radiohead blast EMI over release of ‘Greatest Hits’ album

RadioheadRadiohead frontman Thom Yorke has spoken out against the band’s former record label, EMI, over their plans to release a ‘Greatest Hits’ album against the group’s wishes.


The rockers’ contract with the label ended last year; and they decided to giveaway their current album, ‘In Rainbows’, as a free download before releasing it with XL, the same label who had also put out Yorke’s 2006 solo album ‘The Eraser’.


Says Yorke, “We haven’t really had any hits so what exactly is the purpose?




See Also

Wednesday 4 June 2008

Vaughn

Vaughn   
Artist: Vaughn

   Genre(s): 
Rock
   



Discography:


Fearless   
 Fearless

   Year: 2004   
Tracks: 9




 





Kate Hudson - Hudson Doing Well After Wilson Split

Thursday 29 May 2008

Friend believes Ledger was anxious

A close friend of the late Australian actor Heath Ledger has said that he was anxious over the Christmas holidays about not seeing enough of his two-year-old daughter and his split with actress Michelle Williams.
The 28-year-old actor was found dead at his New York apartment on Tuesday; results of an autopsy conducted yesterday were inconclusive.
Reuters reports that in an interview with the West Australian newspaper, model Sophie Ward said that Ledger was worried about his split with actress Michelle Williams and their daughter Matilda during his Christmas holidays at home in Perth.
During the interview, Ward said: "We went to the movies and just did normal stuff... but he was a bit edgy. He couldn't really relax."
She continued: "He said he was going to London but was quite upset because he couldn't see his daughter as much as he'd like to. He was travelling so much and I think he was just frustrated with it all."
"He was clean and wasn't drinking any alcohol or taking drugs," said the model.
She added: "He smoked cigarettes, but that's about it. He was drinking diet Coke when we were together and he said he was very committed to not drinking alcohol. I don't believe he took his own life deliberately."
Police are treating Ledger's death as possibly drug-related and said sleeping pills were found close to his body.
But a spokeswoman for the medical examiner's office said on Wednesday that an autopsy had proved inconclusive and further tests were needed - which could take around 10 days.
The West Australian newspaper says that before Ledger returned to the US from Perth, he left a message with the film editor of the newspaper, thanking the media for leaving him alone.
He said: "I don't know whether it's a conscious thing or an unconscious thing, giving me space and respecting my privacy. It's just been awesome."
He continued: "I've had the most beautiful time back here and being able to see all my friends and family ... It's really enabled me to be a boy again from home and feel like I'd never left. It's truly been an incredibly therapeutic and a much-needed trip home..."
To view a special gallery on the life and career of Heath Ledger, click here.